Great Novel Therapeutics Biotech & Medicals (ROCO:7427) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
42 GF Score
Price NT$72.70
GF Value NT$25.88
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals FFO?

FFO (Funds from operations) only applies to REITs.

ROCO:7427
42GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$72.70 is trading 180.9% above its estimated GF Value™ of NT$25.88. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • FFO:
  • GF Value™: NT$25.88 vs. price of NT$72.70 (180.9% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
42GF Score

Get the complete analysis for ROCO:7427

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$72.70
Price
NT$25.88
GF Value